- Global Pharma News & Resources

The IMA Group Announces Acquisition of MedPlus Disability Evaluations

Newest acquisition adds 7 states to IMA’s network and expands national footprint and service area

TARRYTOWN, N.Y.--(BUSINESS WIRE)--The IMA Group (IMA) announced today the acquisition of MedPlus Disability Evaluations, a regional provider of Social Security Disability evaluations throughout the Southeast and Southwest United States. The acquisition furthers IMA’s long-standing commitment to providing quality Social Security Disability Consultative Examinations (CE’s) and positions it to further expand the company’s portfolio of service offerings in rapidly growing markets.

This acquisition marks IMA’s fourth transaction in the past 18 months, and continues the company’s long-term plan to grow organically and through strategic acquisitions. Financial terms for the two privately held companies were not disclosed. MedPlus will continue to operate under its current name, with key leadership and staff remaining in place.

The IMA Group is a leading technology-enabled provider of medical and psychological screening and evaluation services, with more than 30 years’ experience in returning people to work and productivity. Through IMA’s proprietary IT platform, it has been able to support an electronic interface to SSA’s Disability Case Processing System (DCPS), enabling the company to manage and perform disability evaluations through any state Disability Determination Service (DDS) office. IMA’s latest acquisition adds 7 new states (MedPlus currently operates in 10 states; 3 overlap with IMA), and strategically located physicians and other providers specializing in disability evaluations.

IMA now provides medical, psychological and specialty evaluations and related services in more than 30 states, including the recent additions of Alabama, Georgia, Louisiana, Mississippi, New Mexico and North Carolina and South Carolina. Notably, the expansion enhances IMA’s commitment to serving the needs of rural and under-served communities by bringing more convenient access to local providers and clinics.

“Since our founding, disability evaluations have been one of the core services we offer,” said Dr. Mark Weinberger, President of The IMA Group. “Because of our history and expertise, this acquisition marks a natural expansion of our company. It also will help further our strategy for growth by enabling us to market other key services, including occupational and behavioral health, plus general medicine specialty services to a broader cross-section of the country.”

Dr. Claude Earl Fox, President and CEO of MedPlus, will remain with the company and work with the leadership team under IMA’s Government Services division. “Performing disability evaluations is an important service for many Americans, as it can provide much-needed assistance during a difficult time,” said Dr. Fox. “MedPlus shares IMA’s commitment to performing high-quality exams in an efficient, comprehensive and patient-centric manner. We look forward to collaborating as a team to bring the expanded portfolio of programs offered by IMA to our many clinic locations.”

For a full list of services and programs available through The IMA Group, visit

About The IMA Group:

For over 30 years, The IMA Group, headquartered in Tarrytown, New York and with offices nationwide, has been dedicated to helping people get back to work and resume productivity. Over the past 10 years, IMA has conducted more than three million evaluations nationwide, utilizing thousands of providers based both at IMA’s 90+ offices as well as independent locations. We provide Government Services clients with medical, psychological and related evaluations, as well as ancillary services. Payer Services supports Commercial Insurers, TPAs, and Corporate clients with Independent Medical Evaluations, Case Management and Occupational Health Services, Fitness for Duty determinations, Pre-Employment examinations and Forensic Drug Testing. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested participants for pharmaceutical manufacturers. For more information visit


Brenna Harrington
Scott Public Relations

Editor Details

  • Company:
    • Businesswire
Last Updated: 17-Aug-2021